Abstract
Purpose :
To assess the clinical performance of multifocal scleral lens for correction of presbyopia.
Methods :
A prospective clinical trial of Onefit-A multifocal scleral lens (Blanchard Contact Lens INC.) was conducted on 30 participants with presbyopia. At 4 weeks after scleral lens wear, change of far, intermediate, and near visual acuity was evaluated. For evaluation of scleral lens safety, conjunctival hyperemia, corneal staining, corneal neovascularization, central corneal thickness (CCT), corneal endothelial cell count, tear film break-up time (BUT), and binocular stereopsis were examined. Subjective questionnaires for satisfaction (point rated 1 to 5) and discomfort (point rated 0 to 4) were quantified.
Results :
Among 30 participants, 24 participants were enrolled in this study. Six participants were drop out because of poor compliance of lens fitting (4) and follow up loss (2). At 4 weeks after scleral lens wear, far, intermediate and near logMAR visual acuity was 0.08 ± 0.11, 0.10 ± 0.12, 0.01 ± 0.12. This results were significantly improved from baseline uncorrected visual acuity (far: p = 0.004; intermediate: p = 0.004; near: p = 0.002) and were not significantly different from baseline best corrected visual acuity. Conjunctival hyperemia, corneal staining, corneal neovascularization, central corneal thickness (CCT), corneal endothelial cell count, tear film break-up time (BUT), and binocular stereopsis was not significantly different between before and after scleral lens wear. Each average point of satisfaction questionnaires for comfort, corrected far, intermediate, near visual acuity, and handling was 4.1, 3.4, 3.5, 3.5, and 3.4. Each average point of discomfort questionnaires for dryness, irritation, foreign body sensation, redness, fogging, and halo was 0.7, 0.8, 1.0, 0.7, 0.7 and 1.3.
Conclusions :
This multifocal scleral lens offers to presbyops an improvement in far, intermediate, and near visual acuity without serious ocular adverse effect. Therefore it endorses the approach as a safe and effective option for the correction of presbyopia.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.